NCI-H1792 Cells

Unit

3 x 10^6 cells/ml

Cell Type

Tumor Cells

Tissue Type

Lung cancer cell lines

,

NCI cell lines

Organism

Human

Donor History

Lung adenocarcinoma

Growth Properties

Adherent

Growth Conditions

Culture medium: RPMI 1640

,

w: 2.0 mM stable Glutamine

,

w: 2.0 g/L NaHCO3 (Cytion article number 820700a). Supplements: Supplement the medium with 10% FBS. Dissociation reagent: Accutase. Freeze medium: As a cryopreservation medium

,

we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability

,

or CM-1 (Cytion catalog number 800100)

,

which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. Incubation atmosphere: 37°C

,

5% CO2

,

humidified atmosphere.

Immortalization Method
Full Information

https://www.cytion.com/NCI-H1792-Cells/305835

SKU: 305835 Kategorie: ,
Mgr. Otakar Fišer
Máte otázky k tomuto produktu? Kontaktujte našeho specialistu.
Mgr. Otakar Fišer
Produktový manažer - Life Science
Popis

NCI-H1792 is a human non-small cell lung carcinoma (NSCLC) cell line derived from a lung adenocarcinoma of an adult patient. It has been utilized extensively in cancer research, particularly in studies focusing on lung tumorigenesis, genetic aberrations, and drug sensitivity profiling. The cell line is characterized by an epithelial morphology and forms adherent monolayers in culture. Its inclusion in large-scale datasets such as the Cancer Cell Line Encyclopedia (CCLE) has enabled extensive genomic and proteomic profiling, facilitating comparative analyses with other lung cancer models.

Genomically, NCI-H1792 exhibits several molecular alterations common in NSCLC. It is known to harbor a KRAS mutation, a common oncogenic driver in lung adenocarcinoma, which contributes to aberrant MAPK signaling. The cell line has also been analyzed in proteomic studies, where its protein expression profile has provided insight into signaling pathway dependencies and vulnerabilities. Proteomic data highlight its utility in understanding pathway regulation and drug target validation across KRAS-mutant cancers. These datasets also underscore its classification within a subtype of KRAS-driven cancers that show distinct metabolic and signaling characteristics.

O značce

Společnost Cytion vznikla v roce 2004 v německém Heidelbergu s jasným vědeckým posláním: dodávat ověřené lidské a zvířecí buněčné linie bez kontaminace, připravené za přísně kontrolovaných laboratorních podmínek.

Postupně se vypracovala ve spolehlivou buněčnou banku, která slouží akademickým laboratořím, biotechnologickým firmám i farmaceutickým výzkumným týmům po celém světě. Klade přitom důraz na reprodukovatelnost výsledků, přísnou kontrolu kvality a dlouhodobá partnerství.